CTLA4 and neoplasm: Notably, single-cell TCR sequencing confirms that CTLA-4 inhibitors combined with PD-1 blockade synergistically enhance T-cell clone spatiotemporal dynamics, significantly improving anti-tumor immunity breadth and durability [57].